| A syndicate of investors included current shareholders and new shareholders of Azanta. The transaction was successfully completed on 1 October 2015. Magnusson’s team encompassed partner Søren Brinkmann and associate Sebastian Rungby. Azanta is a privately owned specialty pharma company primarily operating within oncology, women’s health and addiction medicine. Azanta seeks to be an international market leader within certain specialty pharma product categories, employing innovative repositioning and drug formulation strategies. Azanta currently markets (or makes available under special authorization) a portfolio of specialty pharmaceutical products, including Nimoral™, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta® for labour induction. For more information please go to: http://www.azanta.com/ |
